期刊名称：JOURNAL OF HEPATOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
|
The Journal of Hepatology publishes original papers, reviews, case reports and letters to the Editor concerned with clinical and basic research in the field of hepatology. The Journal is published in English. Supplements may be accepted after editorial review.
The full text of the Journal of Hepatology is available online via two sources:
Institutional access: If your library has a subscription to ScienceDirect and has elected to include the Journal of Hepatology, you can access the journal online via www.sciencedirect.com.
Please go to www.jhep-elsevier.com to access the Journal of Hepatology online.
- FREE TABLES OF CONTENTS AND ABSTRACTS
- FREE ACCESS TO THE EDITORIAL AND REVIEW ARTICLE OF EACH ISSUE
- FULL TEXT FOR EASL MEMBERS AND PERSONAL SUBSCRIBERS
IMPORTANT: All EASL members have online access included in their membership fee. All personal subscribers have online access included in their subscription rate. |
|
Instructions to Authors
Journal of Hepatology, the official journal of the European Association for the Study of the Liver (EASL), publishes articles describing clinical and basic investigations in the field of Hepatology.
MANUSCRIPT SUBMISSION
Manuscripts must be submitted via the ONLINE Site : jhep.manuscriptcentral.com
Any written enquieres should be addressed to:
Juan Rod¨¦s, M.D., FRCP., Editor
Journal of Hepatology, Hospital Clinic, Villarroel 170
08036 Barcelona, SPAIN
Tel: +34 93 453 6497
Fax: +34 93 454 4525
Email: jhepatol@medicina.ub.es
CATEGORIES OF MANUSCRIPTS
ORIGINAL MANUSCRIPTS. Manuscripts submitted in this category are expected to be concise, well organized, and clearly written. Acceptance of original manuscripts will be based upon originality and importance of the investigation. These manuscripts are reviewed by the Editors and, in most cases, by two experts in the field. Manuscripts requiring extensive revision will be at a disadvantage for publication. Manuscripts are submitted with the understanding that they are original contributions and do not contain data that has been published elsewhere or are under consideration in another journal. Meeting abstracts do not constitute prior publication. Journal of Hepatology strongly discourages the submission of more than one article dealing with related aspects of the same study.
REVIEW ARTICLES. Review articles on selected clinical and basic topics of interest for the readers of Journal of Hepatology will be solicited by the Editors. In exceptional cases, non-invited reviews could be considered for publication. Individuals interested in writing a review article should correspond with the Editor-in-Chief regarding the topic before submitting the entire manuscript. Review articles are expected to be clear, concise and updated. The inclusion of tables and figures to summarize critical points is highly desirable. Review articles are reviewed by the Editors and may be sent to outside expert reviewers before a final decision for publication is made. Revisions may be required.
EDITORIALS. This section consists of invited brief editorial comments on articles published in Journal of Hepatology.
CASE REPORTS. Case reports will be accepted only if they represent an important contribution to the etiology, pathogenesis or treatment of a specific liver disorder. Regular case reports will not be accepted even if they provide interesting clinical information.
LETTERS TO THE EDITOR. Letters to the Editor are welcomed and will be considered for publication. Letters may be related to articles published in recent issues of Journal of Hepatology or to topics of general interest to hepatologists. Instructive case reports are also welcomed in this section. Letters must not be longer than three doubled-spaced pages, including references, and may contain only one table or figure. No more than 6 authors may appear in the author list.
IMAGES IN HEPATOLOGY. This section consists of images of exploratory, radiological or histological features that may be of interest to hepatologists. The image must be accompanied by a brief summary (one double-spaced page) of the case. A maximum of two references can be included. No charges are applied for colour images in the Journal's 'Image Section.'
ORGANIZATION OF THE MANUSCRIPT
The submitted manuscript must contain the following: They must be typed double-spaced throughout and and must be in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see J Hepatol 1997;27:218-230); however, SI units are not compulsory. Authors should complete the checklist for authors and fax this to the editorial office on +34 93 454 4525 once the manuscript has been uploaded. Improperly prepared manuscripts will not be entered into the review process. The number of tables and figures must be stated and uploaded in separate files from the text. It is advised that files are uploaded in either word or as RTF files. Figures can be created and uploaded as either powerpoint files or JPG files. PC-compatible format is required. MAC users should ensure that the file extension is stated.
A letter of submission must be uploaded with all manuscripts, including revised manuscripts (see later) . This should be uploaded in the Comments to the Editor section. This letter may be used to outline the strengths of the study. This letter must be accompanied by another letter (see later) signed by all the authors in the order of the author list, indicating that: 1) in case of acceptance of the manuscript the copyright is transferred to the European Association for the Study of the Liver (EASL); 2) all the listed authors have participated actively in the study; 3) all the authors have read and approved the submitted manuscript; 4) the study complies with current ethical considerations; 5) the manuscript reports unpublished work which is not currently under consideration elsewhere and will not be submitted to another journal until a final decision has been made; and 6) there are no conflicts of interest, unless those identified specifically by the authors in the letter. All these documents should be faxed to the Editorial office on +34 93 454 4525 once the manuscript has been submitted.
All commercial relationships (i.e. consultancies, patent-licensing agreements) that might pose a conflict of interest in connection with the submitted manuscript must be included in the letter.
The manuscript must be arranged as follows: (1) title page, (2) summary, (3) introduction, (4) materials and methods (or patients and methods), (5) results, (6) discussion, (7) acknowledgements, (8) references, (9) tables, (10) figure legends, and (11) figures.
Manuscript length. The manuscript must not be larger than 3,000 words, excluding the abstract, references, tables and figures. An electronic word count must be provided in the title page and where requested during the submission process.
Title page. This page must contain: (1) title; (2) the names of the authors including the first names of all the authors in full; (3) the names of department(s) and institution(s) where the work was done; (4) short title of less than 40 characters to be used as a running head; (5) name, address, telephone and fax numbers and electronic mail address of the corresponding author and (6) electronic word count.
Abstract. The abstract must contain 200 words or less and must be organized as follows: Background/Aims, Methods, Results, and Conclusions. Do not use abbreviations, footnotes or references in the abstract. An electronic word count of the abstract must be included. Provide from three to ten key words at the end of the abstract.
Layout of the paper. Place the first author's last name, the short title and the page number at the top of each page. Manuscripts reporting data from research conducted in humans must include a statement of assurance in the methods section of the manuscript reading that: (1) informed consent was obtained from each patient included in the study and (2) the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee. Manuscripts reporting experiments using animals must include a statement giving assurance that all animals received humane care and that study protocols comply with the institution's guidelines. Statistical methods used should be outlined. Drugs and chemicals should be used by generic name. If trademarks are mentioned, the manufacturer's name and city should be given. All funding sources supporting the work, either public or private, especially those from pharmaceutical companies, must be included in the acknowledgement.
References. Should accord with the system used in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (J Hepatol 1997; 27: 218-30). They should be numbered consecutively in parentheses in the text and listed numerically in the reference list at the end of the text with journal titles abbreviated in the style of Index Medicus. Where there are seven or more authors, list the first six followed by et al. All articles in the list of references should be cited in the text and, conversely, all references cited in the text must be included in the list. Personal communications and unpublished data should be cited directly in the text by the first author, without being numbered.
Article: Sallie R, Cohen AT, Tibbs CJ, Portmann BC, Rayner A, O'Grady JG, et al. Recurrence of hepatitis C following orthotopic liver transplantation: a polymerase chain reaction and histological study. J Hepatol 1994; 21: 536-542.
Book: Scheuer PJ, Lefkovitch JH. Liver Biopsy Interpretation, 5th ed. London: W.B Saunders; 1994.
Article in Book: Schmidt E, Schmidt FS. Clinical pathology of viral hepatitis. In: Deinhardt F, Deinhardt J, editors. Viral Hepatitis. Laboratory and Clinical Science. New York: Marcel Dekker; 1983.p.411-487
Tables. Should be numbered consecutively in the text with Arabic numerals and each typed on a separate sheet with the table number and title centred above the table and explanatory notes below the table.
Figure legends. Should be typed and double spaced. They should be numbered according to the order of citation. Enough information should be provided to permit interpretation of figures without reference to the text.
Figures. These should be uploaded preferably as either powerpoint files or JPG files.
If finally accepted the degree of reduction will be determined by the publisher, but in general it should be assumed that the same degree of reduction will be applied to all figures in the same paper. For photomicrographs, where possible, a scale should appear on the photograph. Colour plates will be reproduced at the expense of the author(s).
Illustrations should be clearly marked with the figure number corresponding to the order in which figures are presented in the text, orientation (top) and author's name. A soft pencil or preferably a felt-tipped pen should be used for marking photographs. The illustrations should be numbered with Arabic numerals. Laser generated line prints are welcome. Photographs of identifiable patients should be accompanied by written permission to publish from the patient.
REVIEW PROCESS
First submission. Once successful submission of a manuscript has taken place, an acknowledgement will be sent by e-mail to the corresponding author. The number of the manuscript should be used by the authors in all communications with the Editorial Office. All the manuscripts will be reviewed by the Editors and, in most cases, by other expert reviewers. After review, the corresponding author will be notified by means of a letter of the decision to accept or reject the manuscript for publication. This letter will be accompanied in most, but not all, cases by the comments of the reviewers. This letter will be sent via email.
Resubmission of manuscripts. In some cases, authors will be invited to submit a revised version of the manuscript for further review. This invitation does not imply, in any case, that the revised version will be accepted for publication. In general, revised manuscripts must be received in the Editorial Office within four months of the date of the first decision, otherwise they will be considered new manuscripts. Instructions for resubmission of manuscripts are identical to those for the first submission, with the exception that all changes made in the revised version of the manuscript should be underlined and that the cover letter must state that the revised manuscript includes has been revised according to the comments made by the Editor and the Reviewers. Ensure that the point by point response to the reviewers is uploaded where requested and the same for the responses to the Editor.
PROOFS
Proofs will be sent to the author(s) to be checked for typographical errors. Changes or additions to the edited manuscript cannot be allowed at this stage. In the case of two or more authors, please indicate to whom the proofs should be sent. Authors should return their proofs within 48 hours, by fax or email if the corrections are minor, to expedite publication. Elsevier will do everything possible to get your article corrected and published as quickly and accurately as possible, both online (ScienceDirect) and in print. Therefore it is important to ensure that all of your corrections are sent back to us in one communication. Subsequent corrections will not be possible, so please ensure your first sending is complete.
All questions arising after acceptance of a paper, especially those concerning proofs, should be directed to the Publisher, Elsevier Ireland Ltd., Elsevier House, Brookvale Plaza, East Park, Shannon, Co. Clare, Ireland, Tel: +353 61 709650; Fax: +353 61 709110; Email: m.darcy@elsevier.com
COVER ILLUSTRATIONS
Cover illustrations will be chosen by the Editors. Authors are encouraged to submit colour figures suitable for publication in the cover at the time of submission of the manuscript. Cover illustrations are published free of charge. Charges are assessed for colour figures used within the article.
REPRINTS
Reprints must be ordered in advance. An order form indicating the cost of the reprints is sent from the Publisher with page proofs. Reprint orders, payments, and inquiries must be forwarded to the Publisher, not to the Editorial Office.
ANNOUNCEMENTS
Announcements of meetings that could be of interest to the readers of Journal of Hepatology should be sent to the Editor at least 4 months before the date of publication. Short announcements are published free of charge. Big announcements are considered as advertising and the prices vary according to the size and the number of insertions.
ADVERTISEMENTS
Information about advertisements in Journal of Hepatology can be obtained from the Publisher.
PERMISSIONS
Permissions may be sought directly from Elsevier's Rights Department in Philadelphia, PA, USA: Tel+1 215 238 7869, Fax +1 215 238 2239, Email healthpermissions@elsevier.com. Requests may also be completed online via the Elsevier homepage (www.elsevier.com).
Copyright assignment, Authorship responsibility, Financial disclosure and Institutional Review Board/Animal Care Committee Approval.
This form should be printed out and signed by all authors and sent to the Editorial Office via Fax +34 93 454 4525, or via post. If this form is not received the paper will not be published if finally accepted.
Drug Declaration Form - This form should be printed out and signed by the corresponding author on behalf of all authors and faxed to the Editorial Office on +34 93 454 4525. This is required when a paper is a drug related study.
Methodological and Statistical instructions for authors submitting manuscripts to Journal of Hepatology
The manuscripts should include a complete and detailed description of what was done.
This includes a description of the design, measurement and collection of data, the study objective and major hypotheses, type and source of subjects, inclusion and exclusion criteria and measures of outcome, number of subjects studied and why this number was chosen. Any deviation from the study protocol should be stated.
The baseline characteristics of any compared groups should be described in detail and - if necessary - adjusted for in the analysis of the outcome. For randomised clinical trials the following should also be clearly documented: treatments, sample size estimation, method of random allocation and measures taken for maintaining its concealment including blinding, numbers treated, followed-up, being withdrawn, dropping out, and having side effects (numbers and type).
The statistical methods used should be relevant and clearly stated. Special or complex statistical methods should be explained and referenced. Complex analyses should be performed with the assistance of a qualified statistician. Unqualified use of such analyses is strongly discouraged. The underlying assumptions of the statistical methods used should be tested to ensure that the assumptions are fulfilled. For small data sets and if variable distributions are non-normal, distribution free (non-parametric) statistical methods should be used. The actual P-values - whether significant or not - should always be presented (not NS). Confidence intervals convey more information than P-values and should be presented whenever possible. Continuous variables can always be summarised using the median and range which are therefore preferred. Only in the infrequent case of a Normal distribution are the mean and standard deviation (SD) useful. Complex analyses (including Cox and logistic regression analysis) should be presented in sufficient detail: i.e. variable scoring, regression coefficients, standard errors and any constants. Odds-ratios or relative risks are not sufficient documentation of such analyses. The handling of any missing values in the data should be clearly specified.
The number of statistical tests performed should be kept at a minimum to reduce spurious positive results. Explorative (hypothesis generating) analyses without confirmation using independent data are discouraged. Figures showing individual observations e.g. scatter plots are encouraged. Histograms may also be useful. Tables should indicate the number of observations on which each result is being based.
RANDOMIZED CONTROLLED TRIALS: Any paper that is an RCT should adhere to the guidelines that can be found at the following web-site: www.consort-statement.org. The checklist should be printed out and faxed to the editorial office.
Editorial Board
- Editor:
- J. Rodés
- Assistant Editor:
- P. Ginès
- Editorial Office:
- Journal of Hepatology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain, Tel: +34-93-453 6497, Fax: +34-93-454 4525, Email: jhepatol@medicina.ub.es
- Associate Editors:
- U. Beuers, Munich, Germany
H.E. Blum, Freiburg, Germany
J. Bruix, Barcelona, Spain
G. García-Tsao, New Haven, USA
J. Heathcote, Toronto, Canada
M. Kojiro, Kurume, Japan
M.U. Mondelli, Pavia, Italy
R.P.J. Oude Elferink, Amsterdam, The Netherlands
M. Pinzani, Firenze, Italy
J. Reichen, Bern, Switzerland
D. Samuel, Villejuif, France
D. Schuppan, Erlangen, Germany
D. Valla, Clichy, France
D. Vergani, London, UK
- Statistical Consultant:
- E. Christensen, Copenhagen, Denmark
- Editorial Assistants:
- N. van Berckel
X. Forns
G. Lopez
R. Poblet
- Founding Editor:
- Dame S. Sherlock, London, UK
- Editors Emeritus:
- J.-P. Benhamou, Paris, France
G. Paumgartner, Munich, Germany
- Editorial Board:
- L. Accatino, Chile
G. Alexander, UK
G. Alpini, US
D. Alvaro, Italy
M.J.P. Arthur, UK
C. Balabaud, France
W.F. Balistreri, US
M. Beaugrand, France
A. Bertoletti, UK
F.P. Bianchi, Italy
L. Bolondi, Italy
A. Bomzon, Israel
F. Bortolotti, Italy
J. Bosch, Spain
P. Brissot, France
R. Butterworth, Canada
M.-H. Chang, Taiwan
D.-S. Chen, Taiwan
R. De Mann, The Netherlands
V.J. Desmet, Belgium
J.-F. Dufour, Switzerland
E. Elias, UK
R. Esteban, Spain
G. Fattovich, Italy
A. Gatta, Italy
A. Geerts, Belgium
G. Gerken, Germany
A. Geubel, Belgium
G. Gores, US
N. Hayashi, Japan
S. Hirohashi, Japan
E.A. Jones, The Netherlands
E.B. Keeffe, US
D. Kershonobich, Mexico
M.C. Kew, South Africa
R.E. Kirsch, South Africa
M.J. Koziel, US
S. Krähenbühl, Switzerland
G.A. Kullak-Ublick, Switzerland
B.H. Lauterburg, Switzerland
J.T. Liang, US
S. Locarnini, Australia
A. Lok, US
A. Mallat, France
F. Marra, Italy
J.M. Mato, Spain
D. Meijer, The Netherlands
G. Mieli-Vergani, UK
K. Moore, UK
R. Moreno-Otero, Spain
H. Moshage, The Netherlands
M. Navasa, Spain
F. Negro, Switzerland
J. Neuberger, UK
P. Neuhaus, Germany
O. Niemel?/B>, Finland
J. O'Grady, UK
H. Okamoto, Japan
K. Okita, Japan
M. Ornata, Japan
L. Pagliaro, Italy
M. Parola, Italy
J.-M. Pawlotsky, France
L.W. Powell, Australia
R.H. Purcell, US
G. Raimondo, Italy
J.L. Rakela, US
G. Ramadori, Germany
B. Rehermann, US
F. Salerno, Italy
T. Sauerbruch, Germany
E. Schrumpf, Norway
A. Smedile, Italy
J.A. Solís-Herruzo, Spain
U. Spengler, Germany
B. Stieger, Switzerland
A. Stiehl, Germany
M. Strazzabosco, Italy
E. Tabor, US
N. Tassopoulos, Greece
R. Terg, Argentina
H. Thomas, UK
H. Tilg, Austria
M. Trauner, Austria
C. Trautwein, Germany
F. Trevisani, Italy
R. Tur-Kaspa, Israel
G. Van Berge Henegouwen, The Netherlands
K.J. Van Erpecum, The Netherlands
H. Vilstrup, Denmark
A.W. Wolkoff, US
T. Wright, US
|
